2025-04-16 - Analysis Report
## Teva Pharmaceutical Industries Ltd ADR (TEVA) Stock Review

**0) Overview:** Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company producing generic and specialty medicines.

**1) Performance Comparison:**

* **TEVA Cumulative Return:** 31.03%
* **VOO (S&P 500) Cumulative Return:** 66.27%
* **Return Difference:** -35.2%  (TEVA underperformed VOO by 35.2 percentage points).
* **Relative Divergence:** 60.4% (Indicates TEVA's current underperformance is relatively closer to its historical minimum underperformance than its maximum overperformance, based on provided data).

The provided Alpha and Beta analysis reveals significant underperformance compared to the S&P 500 (negative Alpha) across multiple periods, with Beta values mostly exceeding 1, suggesting higher volatility than the market.  The recent positive CAGR (2022-2024) is notable but needs further investigation concerning its sustainability.  Market capitalization fluctuates considerably.


**2) Recent Price Movement:**

* **Closing Price:** $13.60
* **5-Day Moving Average:** $13.53
* **20-Day Moving Average:** $14.83
* **60-Day Moving Average:** $16.53

The price is below all three moving averages, suggesting a downtrend.

**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4175 (Medium Risk)
* **RSI:** 31.50 (Suggests oversold conditions, but this should be considered cautiously given the negative trend).
* **PPO:** -0.72 (Negative value indicating bearish momentum).
* **20-Day Relative Divergence Change:** -8.8% (Short-term downtrend).
* **Expected Return:** -45.0% (This represents a significant expected underperformance relative to the baseline, implying a high level of risk).  Considering the negative Alpha and historical underperformance, this figure should be carefully considered. Long-term (2+ years) investment requires careful risk assessment due to this high risk factor.  A long term strategy should include a thorough re-evaluation of this estimate against changing market conditions and company performance.


**4) Recent Earnings Analysis:**

| Date       | EPS     | Revenue      |
|------------|---------|---------------|
| 2024-11-06 | -$0.39  | $4.33 Billion |
| 2024-07-31 | -$0.75  | $4.16 Billion |
| 2024-05-08 | -$0.12  | $3.82 Billion |
| 2023-11-09 | $0.07   | $3.85 Billion |
| 2024-02-12 | $0.06   | $3.85 Billion |

Recent earnings show significant volatility and recent negative EPS.  Further analysis is needed to determine the underlying causes of these fluctuations and their impact on future performance.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31 | $4.23B      | 50.15%        |
| 2024-09-30 | $4.33B      | 49.60%        |
| 2024-06-30 | $4.16B      | 48.61%        |
| 2024-03-31 | $3.82B      | 46.37%        |
| 2023-12-31 | $4.46B      | 54.18%        |

Revenue is relatively stable, but profit margins have been declining recently.

**Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-12-31 | $5.37B      | -4.04%        |
| 2024-09-30 | $6.07B      | -7.21%        |
| 2024-06-30 | $6.36B      | -13.30%       |
| 2024-03-31 | $7.28B      | -1.91%        |
| 2023-12-31 | $7.51B      | 5.72%         |

Negative ROE in recent quarters indicates a concerning trend in profitability and return on investment.


**6) Overall Analysis:**

TEVA has significantly underperformed the S&P 500 over the analyzed period.  While recent price action shows some potential for a bounce, several indicators point towards a bearish outlook.  Negative EPS, declining profit margins, and negative ROE raise serious concerns about the company's financial health and future prospects.  The high risk level indicated by the expected return and the technical indicators suggests that any investment should be approached with extreme caution. Further investigation into the reasons behind the recent earnings volatility and the sustained underperformance against the market benchmark is crucial before considering any investment in TEVA.  The data suggest TEVA currently represents a high-risk investment.
